| scholarly article | Q13442814 |
| P50 | author | Barbara Burtness | Q89693033 |
| P2093 | author name string | Jing Wang | |
| Jill Gilbert | |||
| Julie E Bauman | |||
| Lori J Wirth | |||
| Antonio Jimeno | |||
| David Raben | |||
| Nabil F Saba | |||
| Ranee Mehra | |||
| Thomas J Galloway | |||
| Alexander D Colevas | |||
| Anna W Ma | |||
| Ruzanna Atoyan | |||
| P2860 | cites work | Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States | Q22306233 |
| Improving the efficacy of chemoradiation with targeted agents | Q26850193 | ||
| Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair | Q26863429 | ||
| HER2 as a therapeutic target in head and neck squamous cell carcinoma | Q27026178 | ||
| Human papillomavirus and survival of patients with oropharyngeal cancer. | Q27851567 | ||
| Cancer statistics, 2014 | Q27861018 | ||
| The mutational landscape of head and neck squamous cell carcinoma | Q29614654 | ||
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
| Novel insight into mutational landscape of head and neck squamous cell carcinoma | Q30441193 | ||
| Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. | Q34171999 | ||
| Targeting HER2 in other tumor types | Q34346131 | ||
| Histone-deacetylase inhibitors: novel drugs for the treatment of cancer | Q34743301 | ||
| Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. | Q35152720 | ||
| Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck | Q35287729 | ||
| A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. | Q35743883 | ||
| Modulation of cellular radiation responses by histone deacetylase inhibitors | Q36389311 | ||
| Epidermal growth factor receptor biology in head and neck cancer | Q36500973 | ||
| Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma | Q36617162 | ||
| Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer | Q37337056 | ||
| Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. | Q38069662 | ||
| Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition | Q38118439 | ||
| Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. | Q38433814 | ||
| Nuclear epidermal growth factor receptor modulates cellular radio-sensitivity by regulation of chromatin access | Q39518179 | ||
| CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity | Q39715181 | ||
| Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members | Q40009294 | ||
| Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci | Q40240295 | ||
| Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors | Q42704536 | ||
| Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study | Q43105772 | ||
| Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. | Q44260431 | ||
| Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. | Q53657859 | ||
| Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival | Q83764762 | ||
| Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial | Q87674625 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemoradiotherapy | Q5090613 |
| P304 | page(s) | 1566-1573 | |
| P577 | publication date | 2015-01-08 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma | |
| P478 | volume | 21 |
| Q36978557 | CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy |
| Q38637354 | Dual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancers |
| Q28067666 | Epigenetic polypharmacology: from combination therapy to multitargeted drugs |
| Q64119667 | GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer |
| Q38947405 | HDACs and HDAC Inhibitors in Cancer Development and Therapy |
| Q93080888 | Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors |
| Q102211000 | Moving targets in drug discovery |
| Q38739347 | Multitarget Drugs: an Epigenetic Epiphany. |
| Q47243959 | SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis |
| Q38253835 | Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer. |
| Q96341682 | Strategies for testing intervention matching schemes in cancer |
| Q89169966 | Targeting Epigenetics in Cancer |
Search more.